{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:11:54Z","timestamp":1792008714197,"version":"4.4.0"},"reference-count":97,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1080\/10673220902979896","type":"journal-article","created":{"date-parts":[[2009,6,4]],"date-time":"2009-06-04T13:10:39Z","timestamp":1244121039000},"page":"214-225","source":"Crossref","is-referenced-by-count":59,"title":["A Critique of the Dopamine Hypothesis of Schizophrenia and Psychosis"],"prefix":"10.1097","volume":"17","author":[{"given":"Joanna","family":"Moncrieff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1176\/appi.ajp.160.1.13","article-title":"Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia.","volume":"160","author":"Kapur","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R2-4-20210129","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain.","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"R3-4-20210129","first-page":"492","article-title":"The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.","volume":"160","year":"1966","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"R5-4-20210129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0022-3956(74)90081-8","article-title":"Dopamine and the pharmacology of schizophrenia: the state of the evidence.","volume":"11","author":"Matthysse","year":"1974","journal-title":"J Psychiatr Res"},{"key":"R6-4-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0010-440X(68)80051-3","article-title":"The role of amines in the etiology of schizophrenia.","volume":"9","author":"Faurbye","year":"1968","journal-title":"Compr Psychiatry"},{"key":"R7-4-20210129","first-page":"233","article-title":"Toward hypotheses for a biochemical component in the vulnerability to schizophrenia.","volume":"4","year":"1972","journal-title":"Semin Psychiatry"},{"key":"R8-4-20210129","first-page":"711","article-title":"L, Jr., Goetz C, Westheimer R. Pathophysiology of schizophrenia and the striatum.","volume":"33","author":"Klawans","year":"1972","journal-title":"Dis Nerv Syst"},{"key":"R9-4-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1176\/ajp.127.2.199","article-title":"H, Taylor K M, Coyle J T, Meyerhoff J L. The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs.","volume":"127","author":"Snyder","year":"1970","journal-title":"Am J Psychiatry"},{"key":"R10-4-20210129","first-page":"200","article-title":"Antipsychotic drug actions: a clue to the neuropathology of schizophrenia.","volume":"32","author":"Matthysse","year":"1973","journal-title":"Fed Proc"},{"key":"R11-4-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","article-title":"The dopamine hypothesis of schizophrenia: a review.","volume":"2","year":"1976","journal-title":"Schizophr Bull"},{"key":"R12-4-20210129","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"L, Kahn R S, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization.","volume":"148","author":"Davis","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"suppl 1","key":"R14-4-20210129","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1055\/s-2006-931483","article-title":"The neurochemical circuitry of schizophrenia.","volume":"39","author":"Carlsson","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"suppl 1","key":"R15-4-20210129","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1055\/s-2006-931498","article-title":"Cortical microcircuits in schizophreniathe dopamine hypothesis revisited.","volume":"39","author":"Winterer","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"R16-4-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2005.02.007","article-title":"R, Woolley J B, Tabraham P, et al. What causes the onset of psychosis.","volume":"79","author":"Broome","year":"2005","journal-title":"Schizophr Res"},{"key":"R17-4-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(06)78001-1","article-title":"Neurobiology of dopamine in schizophrenia.","volume":"78","author":"Guillin","year":"2007","journal-title":"Int Rev Neurobiol"},{"issue":"suppl 2","key":"R18-4-20210129","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00019052-200312002-00002","article-title":"Dopamine: a key regulator to adapt action, emotion, motivation and cognition.","volume":"16","author":"Nieoullon","year":"2003","journal-title":"Curr Opin Neurol"},{"key":"R19-4-20210129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/brain\/awg035","article-title":"K, Messa C, Lawrence A D, Grasby P M, Piccini P, Brooks D J. Dopamine release during sequential finger movements in health and Parkinsons disease: a PET study.","volume":"126","author":"Goerendt","year":"2003","journal-title":"Brain"},{"key":"R20-4-20210129","first-page":"A274","article-title":"Frontal endogenous dopamine release detected with 11C-raclopride PET during a visual search task in healthy subjects and Parkinsons disease patients.","volume":"64","author":"Sawamoto","year":"2005","journal-title":"Neurology"},{"key":"R21-4-20210129","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/sj.npp.1301159","article-title":"Neural substrates of psychostimulant-induced arousal.","volume":"31","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R22-4-20210129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0893-133X(97)00043-2","article-title":"D, Baldwin R M, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans.","volume":"17","author":"Laruelle","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"R23-4-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0893-133X(01)00231-7","article-title":"A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects.","volume":"25","author":"Verhoeff N P, Kapur","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R24-4-20210129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.07.012","article-title":"Subjective and behavioural consequences of striatal dopamine depletion in schizophreniafindings from an in vivo SPECT study.","volume":"88","year":"2006","journal-title":"Schizophr Res"},{"key":"R25-4-20210129","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1023\/A:1022075324164","article-title":"The effects of stress on central dopaminergic neurons: possible clinical implications.","volume":"22","year":"1997","journal-title":"Neurochem Res"},{"key":"R26-4-20210129","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/0091-3057(86)90478-8","article-title":"Urinary monoamine metabolites as indices of mental stress in healthy males and females.","volume":"24","author":"Frankenhaeuser","year":"1986","journal-title":"Pharmacol Biochem Behav"},{"key":"R27-4-20210129","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2466\/pr0.1989.64.3.856","article-title":"Females emotionality as reflected in the excretion of the dopamine metabolite HVA during mental stress.","volume":"64","author":"Rauste-von Wright","year":"1989","journal-title":"Psychol Rep"},{"key":"R28-4-20210129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0006-3223(89)90066-8","article-title":"A.E. Bennett award paper. Experimental approaches to human stress research: assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients.","volume":"26","author":"Breier","year":"1989","journal-title":"Biol Psychiatry"},{"key":"R29-4-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0893-133X(99)00153-0","article-title":"Effects of acute metabolic stress on striatal dopamine release in healthy volunteers.","volume":"22","author":"Adler C M, Elman","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"R30-4-20210129","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1523\/JNEUROSCI.3422-03.2004","article-title":"C, Champagne F, Meaney M J, Dagher A. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using 11Craclopride.","volume":"24","author":"Pruessner","year":"2004","journal-title":"J Neurosci"},{"key":"R31-4-20210129","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/syn.20282","article-title":"J, Mehta M A, Grasby P M. Is psychological stress in man associated with increased striatal dopamine levels A 11Craclopride PET study.","volume":"60","author":"Montgomery","year":"2006","journal-title":"Synapse"},{"key":"R32-4-20210129","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrn1406","article-title":"Dopamine, learning and motivation.","volume":"5","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"R33-4-20210129","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1046\/j.1471-4159.1997.68041511.x","article-title":"L, Redfern P H, Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats.","volume":"68","author":"Marshall","year":"1997","journal-title":"J Neurochem"},{"key":"R34-4-20210129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/syn.20419","article-title":"J, Lingford-Hughes A R, Egerton A, Nutt D J, Grasby P M. The effect of nicotine on striatal dopamine release in man: a 11Craclopride PET study.","volume":"61","author":"Montgomery","year":"2007","journal-title":"Synapse"},{"key":"R35-4-20210129","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1176\/appi.ajp.161.8.1496","article-title":"K, Yu L, Yeh T L, Chiu N T, Chen P S, Lee I H. Associated alterations of striatal dopamine D2D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study.","volume":"161","author":"Yang","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R36-4-20210129","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/01.rlu.0000262980.98342.dd","article-title":"Dopamine transporter binding in smokers and nonsmokers.","volume":"32","author":"Newberg","year":"2007","journal-title":"Clin Nucl Med"},{"key":"R37-4-20210129","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1176\/appi.ajp.157.4.632","article-title":"High levels of dopamine activity in the basal ganglia of cigarette smokers.","volume":"157","author":"Salokangas R K, Vilkman","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R38-4-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/appi.ajp.2007.07020352","article-title":"Association of low striatal dopamine D2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse.","volume":"165","author":"Fehr","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R39-4-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pscychresns.2005.09.008","article-title":"K, Yao W J, McEvoy J P, et al. Striatal dopamine D2D3 receptor availability in male smokers.","volume":"146","author":"Yang","year":"2006","journal-title":"Psychiatry Res"},{"key":"R40-4-20210129","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.pnpbp.2007.08.018","article-title":"K, Yao W J, Yeh T L, et al. Decreased dopamine transporter availability in male smokersa dual isotope SPECT study.","volume":"32","author":"Yang","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R41-4-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000083999","article-title":"Rethinking models of psychotropic drug action.","volume":"74","author":"Moncrieff","year":"2005","journal-title":"Psychother Psychosom"},{"key":"R42-4-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.131.2.222b","article-title":"Haloperidol in normals.","volume":"131","author":"Belmaker R H, Wald","year":"1977","journal-title":"Br J Psychiatry"},{"key":"R43-4-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/(SICI)1099-1077(199803)13:2<113::AID-HUP958>3.0.CO;2-N","article-title":"Immediate effects of droperidol.","volume":"13","author":"Healy","year":"1998","journal-title":"Hum Psychopharmacol"},{"key":"R44-4-20210129","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2125.1990.tb05444.x","article-title":"R, Cooper S M, Pilgrim A J. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers.","volume":"30","author":"McClelland","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"R46-4-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/ajp.117.2.97","article-title":"F, Lasky J J, Klett C J, Hollister L E. Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital.","volume":"117","author":"Casey","year":"1960","journal-title":"Am J Psychiatry"},{"key":"R47-4-20210129","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.1960.03590080086012","article-title":"F, Bennett I F, Lindley C J, Hollister L E, Gordon M H, Springer N N. Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo.","volume":"2","author":"Casey","year":"1960","journal-title":"Arch Gen Psychiatry"},{"key":"R49-4-20210129","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1176\/ajp.148.6.714","article-title":"Benzodiazepines in the treatment of schizophrenia: a review and reappraisal.","volume":"148","author":"Wolkowitz O M, Pickar","year":"1991","journal-title":"Am J Psychiatry"},{"key":"R50-4-20210129","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1176\/ajp.116.11.973","article-title":"W, Dahlstrom W G, Tolley A G. Evaluation of tranquilizing drugs in the management of acute mental disturbance.","volume":"116","author":"Abse","year":"1960","journal-title":"Am J Psychiatry"},{"key":"R51-4-20210129","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.pnpbp.2005.03.001","article-title":"M, Zipursky R B, Kapur S. How antipsychotics work: the patients perspective.","volume":"29","author":"Mizrahi","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R52-4-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action.","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"R53-4-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archpsyc.1972.01750260021004","article-title":"Catecholamines in the brain as mediators of amphetamine psychosis.","volume":"27","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"R54-4-20210129","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/10550490490512834","article-title":"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.","volume":"13","year":"2004","journal-title":"Am J Addict"},{"key":"R55-4-20210129","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/10550490050172209","article-title":"L. Stimulant psychosis: symptom profile and acute clinical course.","volume":"9","author":"Harris","year":"2000","journal-title":"Am J Addict"},{"key":"R56-4-20210129","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/archpsyc.1982.04290040052008","article-title":"G, Johnstone E C, Frith C D. Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics.","volume":"39","author":"Owens","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"R57-4-20210129","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/archpsyc.59.4.332","article-title":"G, Thara R, Padmavati R, Srinivasan T N, Jaipurkar S D. Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonance imaging study.","volume":"59","author":"McCreadie","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R58-4-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0028-3908(64)90012-7","article-title":"T. Mechanism of action of psychomotor stimulant drugs. Significance of dopamine in locomotor stimulant action.","volume":"3","author":"van Rossum","year":"1964","journal-title":"Int J Neuropharmacol"},{"key":"R59-4-20210129","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00404847","article-title":"The effects of noradrenaline on rats behaviour.","volume":"16","year":"1970","journal-title":"Psychopharmacologia"},{"key":"R60-4-20210129","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R61-4-20210129","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","article-title":"Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.","volume":"94","author":"Breier","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R62-4-20210129","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R63-4-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: relationship to illness phases.","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol Psychiatry"},{"key":"R64-4-20210129","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0006-3223(91)90353-N","article-title":"Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome.","volume":"29","author":"Tandon","year":"1991","journal-title":"Biol Psychiatry"},{"key":"R65-4-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/bjp.185.1.5","article-title":"Pituitary volume in psychosis.","volume":"185","author":"Pariante C M, Vassilopoulou","year":"2004","journal-title":"Br J Psychiatry"},{"key":"R66-4-20210129","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1126\/science.6334363","article-title":"F, Wagner H N, Jr., Dannals R F, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain.","volume":"226","author":"Wong","year":"1984","journal-title":"Science"},{"key":"R67-4-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0197-4580(89)80005-3","article-title":"L, Pierce D J, Struble R G, Price D L, Cork L C. Age-related changes in multiple neurotransmitter systems in the monkey brain.","volume":"10","author":"Wenk","year":"1989","journal-title":"Neurobiol Aging"},{"key":"R68-4-20210129","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1126\/science.847477","article-title":"R, Creese I, Snyder S H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.","volume":"196","author":"Burt","year":"1977","journal-title":"Science"},{"key":"R69-4-20210129","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archpsyc.1991.01810320063009","article-title":"P, Hogarty G E, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.","volume":"48","author":"McEvoy","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"R70-4-20210129","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1073\/pnas.0409766102","article-title":"Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis.","volume":"102","author":"Seeman","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R71-4-20210129","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1073\/pnas.91.24.11651","article-title":"Elevated dopa decarboxylase activity in living brain of patients with psychosis.","volume":"91","author":"Reith","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R72-4-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(98)00113-3","article-title":"Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia.","volume":"35","author":"Hietala","year":"1999","journal-title":"Schizophr Res"},{"key":"R73-4-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-9964(96)00102-8","article-title":"H, Paillere-Martinot M L, Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients.","volume":"23","author":"Dao-Castellana","year":"1997","journal-title":"Schizophr Res"},{"key":"R74-4-20210129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0006-3223(99)00109-2","article-title":"Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET.","volume":"46","author":"Lindstrom L H, Gefvert","year":"1999","journal-title":"Biol Psychiatry"},{"key":"R75-4-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-4927(00)00064-0","article-title":"M, Doudet D, Bryant T, Cohen R M, Li S H, Wyatt R J. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography.","volume":"100","author":"Elkashef","year":"2000","journal-title":"Psychiatry Res"},{"key":"R76-4-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nn804","article-title":"S, Kohn P D, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.","volume":"5","author":"Meyer-Lindenberg","year":"2002","journal-title":"Nat Neurosci"},{"key":"R77-4-20210129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/archpsyc.61.2.134","article-title":"Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic 18Ffluorodopa study.","volume":"61","author":"McGowan","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"R78-4-20210129","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1192\/bjp.191.51.s13","article-title":"D, Montgomery A J, Asselin M C, Murray R M, Grasby P M, McGuire P K. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis.","volume":"51","author":"Howes","year":"2007","journal-title":"Br J Psychiatry Suppl"},{"key":"R79-4-20210129","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R80-4-20210129","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1176\/appi.ajp.159.10.1718","article-title":"N, Liddle P F, Lam R W, et al. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania.","volume":"159","author":"Yatham","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R81-4-20210129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0006-3223(01)01089-7","article-title":"V, Oquendo M A, Zea-Ponce Y, et al. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression.","volume":"50","author":"Parsey","year":"2001","journal-title":"Biol Psychiatry"},{"key":"R82-4-20210129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1176\/appi.ajp.158.2.314","article-title":"Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation.","volume":"158","author":"Martinot","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R83-4-20210129","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.biopsych.2004.01.023","article-title":"Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder.","volume":"55","author":"Denys","year":"2004","journal-title":"Biol Psychiatry"},{"key":"R84-4-20210129","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/ajp.156.8.1209","article-title":"J, Matochik J A, Pascualvaca D, Jons P H, Cohen R M. High midbrain 18FDOPA accumulation in children with attention deficit hyperactivity disorder.","volume":"156","author":"Ernst","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R85-4-20210129","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1523\/JNEUROSCI.18-15-05901.1998","article-title":"J, Matochik J A, Jons P H, Cohen R M. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A fluorine-18fluorodopa positron emission tomographic study.","volume":"18","author":"Ernst","year":"1998","journal-title":"J Neurosci"},{"key":"R86-4-20210129","first-page":"345","article-title":"Status of the dopaminergic system in post-mortem brain in schizophrenia.","volume":"24","author":"Reynolds G P, Czudek","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"R87-4-20210129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/00207459308987216","article-title":"A meta-analysis of homovanillic acid concentrations in schizophrenia.","volume":"73","year":"1993","journal-title":"Int J Neurosci"},{"key":"R88-4-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0006-3223(99)00257-7","article-title":"Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with (123)Ibeta-CIT.","volume":"47","author":"Laruelle","year":"2000","journal-title":"Biol Psychiatry"},{"key":"R89-4-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0920-9964(03)00006-9","article-title":"C, Lin K J, Liu C Y, Tzen K Y, Yen T C. Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1.","volume":"65","author":"Hsiao","year":"2003","journal-title":"Schizophr Res"},{"key":"R90-4-20210129","first-page":"1319","article-title":"Dopamine receptors and schizophrenia: the neuroleptic drug problem.","volume":"20","author":"Reynolds G P, Riederer","year":"1981","journal-title":"Neuropharmacology"},{"key":"R91-4-20210129","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archpsyc.1982.04290090001001","article-title":"V, Iversen L L, Rossor M, et al. Increased brain dopamine and dopamine receptors in schizophrenia.","volume":"39","author":"Mackay","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"R92-4-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01250639","article-title":"3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.","volume":"75","author":"Kornhuber","year":"1989","journal-title":"J Neural Transm"},{"key":"R93-4-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00429171","article-title":"Dopaminergic supersensitivity after neuroleptics: time-course and specificity.","volume":"60","author":"Muller","year":"1978","journal-title":"Psychopharmacology (Berl)"},{"key":"R94-4-20210129","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1126\/science.2878495","article-title":"F, Wagner H N, Jr., Tune L E, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.","volume":"234","author":"Wong","year":"1986","journal-title":"Science"},{"key":"R95-4-20210129","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(86)92525-0","article-title":"C, Owens D G, Crow T J, et al. Dopamine D2 receptors in schizophrenia studied in vivo.","volume":"2","author":"Crawley","year":"1986","journal-title":"Lancet"},{"key":"R96-4-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archpsyc.1990.01810150013003","article-title":"D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with 11Craclopride.","volume":"47","author":"Farde","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"R97-4-20210129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0925-4927(95)02732-D","article-title":"No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and 11CN-methylspiperone.","volume":"61","author":"Nordstrom A L, Farde","year":"1995","journal-title":"Psychiatry Res"},{"key":"R98-4-20210129","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","article-title":"Prefrontal dopamine D1 receptors and working memory in schizophrenia.","volume":"22","author":"Abi-Dargham","year":"2002","journal-title":"J Neurosci"},{"key":"R99-4-20210129","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/385634a0","article-title":"Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.","volume":"385","author":"Okubo","year":"1997","journal-title":"Nature"},{"key":"R100-4-20210129","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/appi.ajp.159.5.761","article-title":"PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia.","volume":"159","author":"Karlsson","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R101-4-20210129","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/hmg\/ddm347","article-title":"A network of dopaminergic gene variations implicated as risk factors for schizophrenia.","volume":"17","author":"Talkowski M E, Kirov","year":"2008","journal-title":"Hum Mol Genet"}],"container-title":["Harvard Review of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1080\/10673220902979896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T22:32:15Z","timestamp":1739140335000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00023727-200905000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1080\/10673220902979896","relation":{},"ISSN":["1067-3229"],"issn-type":[{"value":"1067-3229","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}